Digestive Diseases and Sciences

, Volume 52, Issue 6, pp 1535–1539 | Cite as

Liver Fibrosis Is Associated with Decreased Peripheral Platelet Count in Patients with Chronic Hepatitis B and C

  • Zeki Karasu
  • Fatih Tekin
  • Galip Ersoz
  • Fulya Gunsar
  • Yucel Batur
  • Tankut Ilter
  • Ulus S. Akarca
CASE REPORT

Abstract

Thrombocytopenia is a common complication of chronic liver diseases, but its pathogenesis is not clear. Although generally attributed to hypersplenism, other factors should also be considered. We investigated the relationship between the peripheral platelet count and the degree of fibrosis in patients with chronic viral hepatitis. In an effort to avoid the effects of hypersplenism, we excluded patients with splenomegaly and/or bi- or pan-cytopenia. Seven hundred eighty-four patients (265 chronic viral hepatitis C and 519 chronic viral hepatitis B) were included in the study. Univariate analysis showed that the peripheral platelet count had a negative correlation with fibrosis score, necroinflammatory activity, and age in both groups. In multivariate analysis, the peripheral platelet count had a similar correlation with the fibrosis score and age, but not with necroinflammatory activity, in both groups. The peripheral platelet count decreased more significantly in females with chronic hepatitis C but not in the chronic hepatitis B group. In conclusion, a decrease in peripheral platelet count may be a sign of an increase in the degree of fibrosis during the course of chronic viral hepatitis B and C and factors other than hypersplenism may play a role in this decrease in the peripheral platelet count.

Keywords

Chronic viral hepatitis Fibrosis Platelet count 

References

  1. 1.
    Morlock CG, Hall BE (1943) Association of cirrhosis, thrombocytopenia and hemorrhagic tendency. Arch Intern Med 72:69–77Google Scholar
  2. 2.
    Felix WR Jr, Myerson RM, Sigel B, Perrin EB, Jackson FC (1974) The effect of portacaval shunt on hypersplenism. Surg Gynecol Obstet 139:899–903PubMedGoogle Scholar
  3. 3.
    Soper NJ, Rikkers LF (1982) Effect of operations for variceal hemorrhage on hypersplenism. Am J Surg 144:70CrossRefGoogle Scholar
  4. 4.
    Morris PW, Patton TB, Balint JA, Hirschowitz BI (1962) Portal hypertension, congestive splenomegaly, and portacaval shunt. Gastroenterology 42:555–559Google Scholar
  5. 5.
    Mutchnick MG, Lerner E, Conn HO (1980) Effect of portacaval anastamosis on hypersplenism. Dig Dis Sci 25:929–938PubMedCrossRefGoogle Scholar
  6. 6.
    Hutson DG, Zeppa R, Levi JU, Schiff ER, Livingstone AS, Fink P (1977) The effect of the distal splenorenal shunt on hypersplenism. Ann Surg 185:605–612PubMedCrossRefGoogle Scholar
  7. 7.
    Frick V (1967) Thrombocytopenie und lebercirrhose. Scweiz Med Wochens 97:407–413Google Scholar
  8. 8.
    Fiore LD, Brophy MT, Deykin D (2003) Hemostasis. In: Zackim D, Boyer TD (eds) Hepatology: A textbook of liver disease. 4th edn. pp 562–563Google Scholar
  9. 9.
    Omata M (1998) Screening for hepatocellular carcinoma. In: Advances in therapeutic hepatology: A word view. Postgraduate course book. University of Chicago Press, Chicago, pp. 49–53Google Scholar
  10. 10.
    Moschcowitz E (1948) The pathogenesis of splenomegaly in hypertension of the portal circulation: “congestive splenomegaly.” Medicine 27:187–221PubMedGoogle Scholar
  11. 11.
    Landolfi R, Leone G, Fedeli G, Storti S, Laghi F, Bizzi B (1980) Platelet-associated IgG in acute and chronic hepatic diseases. Scand J Haematol 25:417–422PubMedCrossRefGoogle Scholar
  12. 12.
    de Noronha R, Taylor BA, Wild G, Triger DR, Greaves M (1991) Interrelationships between platelet count, platelet IgG, serum IgG, immune-complexes and severity of liver disease. Clin Lab Haematol 13:127–135PubMedCrossRefGoogle Scholar
  13. 13.
    Skootsky SA, Rosove MH, Langley MB (1986) Immune thrombocytopenia and response to splenectomy in chronic liver disease. Arch Intern Med 146:555–557PubMedCrossRefGoogle Scholar
  14. 14.
    Paramo JA, Rocha E (1993) Hemostasis in advanced liver disease. Semin Thromb Hemost 19:184–190PubMedCrossRefGoogle Scholar
  15. 15.
    Wehmeier A, Scharf RE, Schneider W (1990) Influence of splenectomy on platelet morphometry and function. Klin Wochenschr 68:847–852PubMedCrossRefGoogle Scholar
  16. 16.
    Thomas HC, McSween RN, White RG (1973) Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet 1:1288–1291PubMedCrossRefGoogle Scholar
  17. 17.
    Triger DR, Wright R (1973) Hyperglobulinaemia in liver disease. Lancet 1:1494–1496PubMedCrossRefGoogle Scholar
  18. 18.
    Kew MC (1996) Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med 16:395–406PubMedGoogle Scholar
  19. 19.
    MacPherson AI, Innes J (1953) Peripheral blood picture after operation for portal hypertension. Lancet 1:1120–1123PubMedCrossRefGoogle Scholar
  20. 20.
    Vang J, Simert G, Hansson JA, Thylen U, Bengmark TS (1977) Results of a modified distal spleno–renal shunt for portal hypertension. Ann Surg 185:224–228PubMedCrossRefGoogle Scholar
  21. 21.
    Sullivan BH Jr, Tumen HJ (1961) The effect of portacaval shunt on thrombocytopenia associated with portal hypertension. Ann Intern Med 55:598–603PubMedGoogle Scholar
  22. 22.
    Karasu Z, Gurakar A, Kerwin B, Hulagu S, Jazzar A, McFadden R, Nour B, Sebastian A, Cassidy F, Stokes K, Van Thiel DH, Wright H (2000) Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 45:1971–1976.Google Scholar
  23. 23.
    Patton TB, Johnston CG, Lyons C, Jordan P Jr (1959) Lateral portacaval anastomosis for portal hypertension: long term results in 58 patients with intrahepatic portal bed block and 7 patients with extrahepatic portal bed block. Am J Gastroenterol 32:291–310PubMedGoogle Scholar
  24. 24.
    Puttini M, Marni A, Montes F, Belli L (1979) Effect of portasystemic shunt on hypersplenism: Clinical study in 129 patients with cirrhosis. Am Surg 45:444–448PubMedGoogle Scholar
  25. 25.
    Ferrara J, Ellison EC, Martin EW Jr, Cooperman M (1979) Correction of hypersplenism following distal splenorenal shunt. Surgery 86:570–573PubMedGoogle Scholar
  26. 26.
    Malt RA (1976) Portasystemic venous shunts (part 1). N Engl J Med 295:24–29PubMedCrossRefGoogle Scholar
  27. 27.
    Marni A, Trojsi C, Belli L (1981) Distal splenorenal shunt. Hemodynamic advantage over total shunt and influence on clinical status, hepatic function and hypersplenism. Am J Surg 142:372–376Google Scholar
  28. 28.
    LaBerge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Somberg KA, Roberts JP, Ascher NL (1993) Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 187:413–420PubMedGoogle Scholar
  29. 29.
    Lawrence SP, Lezotte DC, Durham JD, Kumpe DA, Everson GT, Bilir BM (1995) Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis. Dig Dis Sci 40:1575–1580CrossRefGoogle Scholar
  30. 30.
    Alvarez OA, Lopera GA, Patel V, Encarnacion CE, Palmaz JC, Lee M (1996) Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol 91:134–137PubMedGoogle Scholar
  31. 31.
    Sungaran R, Markovic B, Chong BH (1997) Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 89:101–107PubMedGoogle Scholar
  32. 32.
    Martin TG 3rd, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA (1997) Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 127:285–288PubMedGoogle Scholar
  33. 33.
    Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, Steininger R, Muhlbacher F, Gangl A (1997) Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 27:127–131PubMedCrossRefGoogle Scholar
  34. 34.
    Ishikawa T, Ichida T, Matsuda Y, Sugitani S, Sugiyama M, Kato T, Miyazaki H, Asakura H (1998) Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol 13:907–913PubMedGoogle Scholar
  35. 35.
    Stiegler G, Stohlawetz P, Peck-Radosavljevic M, Jilma B, Pidlich J, Wichlas M, Hocker P, Panzer S (1998) Direct evidence for an increase in thrombopoiesis after liver transplantation. Eur J Clin Invest 28:755–759PubMedCrossRefGoogle Scholar
  36. 36.
    Yanaga K, Tzakis AG, Shimada M, Campbell WE, Marsh JW, Stieber AC, Makowka L, Todo S, Gordon RD, Iwatsuki S (1989) Reversal of hypersplenism following orthotopic liver transplantation. Ann Surg 210:180–183PubMedCrossRefGoogle Scholar
  37. 37.
    Hutchison DE, Genton E, Porter KA, Daloze PM, Huguet C, Brettschneider L, Groth CG, Starzl TE (1968) Platelet changes following clinical and experimental hepatic homotransplantation. Arch Surg 97:27–33PubMedGoogle Scholar
  38. 38.
    Rinkes IH, Van der Hoop AG, Hesselink EJ, Metselaar H, De Rave S, Zonderland HM, Schalm SW, Terpstra OT (1991) Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology 100:1126–1128Google Scholar
  39. 39.
    Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, Kato N, Yoshida Y, Shiina S, Omata M (1999) Platelet count reflects stage of chronic hepatitis C. Hepatol Res 15:192–200CrossRefGoogle Scholar
  40. 40.
    Matsumuro H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y (2000) Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C—a study of 527 patients at one establishment. J Viral Hepat 7:268–275CrossRefGoogle Scholar
  41. 41.
    Okubo M, Shiota G, Kawasaki H (2000) Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond) 99:207–214CrossRefGoogle Scholar
  42. 42.
    Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T (2001) Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 96:3142–3146PubMedCrossRefGoogle Scholar
  43. 43.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435PubMedCrossRefGoogle Scholar
  44. 44.
    Fusegawa H, Shiraishi K, Ogasawara F, Shimizu M, Haruki Y, Miyachi H, Matsuzaki S, Ando Y (2002) Platelet activation in patients with chronic hepatitis C. Tokai J Exp Clin Med 27:101–106PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Zeki Karasu
    • 1
    • 2
  • Fatih Tekin
    • 1
  • Galip Ersoz
    • 1
  • Fulya Gunsar
    • 1
  • Yucel Batur
    • 1
  • Tankut Ilter
    • 1
  • Ulus S. Akarca
    • 1
  1. 1.Department of GastroenterologyEge University Medical SchoolIzmirTurkey
  2. 2.Ege Üniversites i Tıp FakültesiGastroenteroloji Bilim DalıBornovaTurkey

Personalised recommendations